These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 17953381

  • 1. [Analysis of reference range responsible to normal percent value of free prostate specific antigen from men without prostate disease].
    Zhang P, Wang ZM, Chong T, Zhao LH.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):871-3, 903. PubMed ID: 17953381
    [Abstract] [Full Text] [Related]

  • 2. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME.
    Clin Lab Sci; 2001 Sep; 14(2):102-7. PubMed ID: 15625982
    [Abstract] [Full Text] [Related]

  • 3. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW.
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [Abstract] [Full Text] [Related]

  • 4. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C, Jung K, Nakamura T, Yousef GM, Kristiansen G, Diamandis EP.
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [Abstract] [Full Text] [Related]

  • 5. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K, Hoesel W, Reiche J, Deger S, Kramer J, Loening SA, Lein M, Stephan C.
    Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
    [Abstract] [Full Text] [Related]

  • 6. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, Babaian R, Childs SJ, Stamey T, Fritsche HA, Sokoll L, Chan DW, Thiel RP, Cheli CD.
    J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
    [Abstract] [Full Text] [Related]

  • 7. Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients.
    Battikhi MN.
    Prostate Cancer Prostatic Dis; 2003 Nov; 6(3):256-60. PubMed ID: 12970732
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, Veltri RW.
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [Abstract] [Full Text] [Related]

  • 9. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH, Magnabosco WJ, Mauad EC, Carvalho AL.
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [Abstract] [Full Text] [Related]

  • 10. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 11. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR, Wojno KJ, Henricks W, England BA, Vessella RL, Lange PH, Wright GL, Schellhammer PF, Weigand RA, Olson RM, Dowell BL, Borden KK, Oesterling JE.
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [Abstract] [Full Text] [Related]

  • 12. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y, Ozono S, Kagebayashi Y, Yoshi M, Tani Y, Uemura H, Momose H, Okajima E.
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [Abstract] [Full Text] [Related]

  • 13. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW, Liu G, Sheng BW.
    Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
    Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ.
    Urol Oncol; 2005 Jun; 23(1):16-21. PubMed ID: 15885578
    [Abstract] [Full Text] [Related]

  • 15. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Parson RE, Loveland KG.
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [Abstract] [Full Text] [Related]

  • 16. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH, Roobol M, Jenster G, Schröder FH, Bangma CH.
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [Abstract] [Full Text] [Related]

  • 17. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    Zhigang Z, Jieming L, Su L, Wenlu S.
    J Surg Oncol; 2007 Jul 01; 96(1):54-61. PubMed ID: 17345593
    [Abstract] [Full Text] [Related]

  • 18. The use of percent free prostate specific antigen for staging clinically localized prostate cancer.
    Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW.
    J Urol; 1998 Apr 01; 159(4):1238-42. PubMed ID: 9507844
    [Abstract] [Full Text] [Related]

  • 19. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection.
    Canto EI, Singh H, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawin KM.
    J Urol; 2004 Sep 01; 172(3):900-4. PubMed ID: 15310993
    [Abstract] [Full Text] [Related]

  • 20. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
    Partin AW, Criley SR, Subong EN, Zincke H, Walsh PC, Oesterling JE.
    J Urol; 1996 Apr 01; 155(4):1336-9. PubMed ID: 8632568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.